Key facts
- It has raised $6.1M; the latest was Accelerator/Incubator in Apr 2025.
- Notable investors include Almi Invest, Nordic Mentor Network For Entrepreneurship, Eir Ventures, Flerie, Monesi Forvaltnings — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Strike Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Strike Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Strike Pharma
Developer of individual-based cancer treatment designed to provide scalable personalized immunotherapy. The company uses an antibody-based method based on the genetic profile of each patient's tumor that attacks the tumor cells and leaves other normal cells in the body alone, enabling patients to get an affordable and effective treatment while reducing the risk of side effects.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2020
- Employees
- 10
- Website
- strikepharma.com/
- Ownership
- Privately Held (backing)
Strike Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Strike Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Strike Pharma in its N-PORT filings yet. We sweep new filings monthly.